Results 41 to 50 of about 3,505 (170)

The Benefits of Adding Non‐Antimuscarinic Pharmaceuticals in Combination With Beta‐3 Agonists for Overactive Bladder Treatment: A Systematic Review

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Antimuscarinics, as the current first‐line pharmacologic therapies for overactive bladder, exhibit low patient adherence and high rates of reported side effects. As a modern alternative pharmaceutical treatment, beta‐3 agonists, which relax the urinary bladder, may be more tolerable for patients, increasing adherence and ...
Felicity Smith, Charlotte Phelps, Christian Moro   +2 more
wiley   +1 more source

Association Between the Neurogenic Bladder Symptom Score and Urodynamic Examination in Multiple Sclerosis Patients With Lower Urinary Tract Dysfunction [PDF]

International Neurourology Journal, 2015
Purpose: To determine the relationship between the neurogenic bladder symptoms score (NBSS) and urodynamic examination in patients affected by multiple sclerosis (MS) and related lower urinary tract dysfunction (LUTD).
Eugenia Fragalà, Giorgio Ivan Russo, Alessandro Di Rosa, Raimondo Giardina, Salvatore Privitera, Vincenzo Favilla, Francesco Patti, Blayne Welk, Sebastiano Cimino, Tommaso Castelli, Giuseppe Morgia   +10 more
doaj   +1 more source

Development and Validation of Urodynamic Report Writer: A Chat GPT App

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objective Accurate interpretation and reporting of urodynamic studies are essential for diagnosis and management of lower urinary tract dysfunction, yet remain time‐consuming and operator‐dependent. To develop and validate the Urodynamic Report Writer App (URapp), a GPT‐4o‐based virtual assistant that supports interpretation of clinician ...
Riccardo Lombardo, Carolina Cerullo, Marta Santioni, Emanuele Pillitteri, Claudia Lorenti, Sabrina De Cillis, Cristian Fiori, Giorgia Tema, Antonio Franco, Beatrice Turchi, Matteo Romagnoli, Antonio Nacchia, Antonio Cicione, Antonio Pastore, Andrea Fuschi, Andrea Tubaro, Cosimo De Nunzio   +16 more
wiley   +1 more source

Beyond prostate, beyond surgery and beyond urology: The “3Bs” of managing non-neurogenic male lower urinary tract symptoms

Asian Journal of Urology, 2019
Lower urinary tract symptoms (LUTS), consisting storage, voiding and post-micturition symptoms, is a comprehensive definition involving symptoms that may occur due to several causes. Instead of simply focusing on the enlarged prostate, more attention has
Qixiang Song, Paul Abrams, Yinghao Sun
doaj   +1 more source

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin. [PDF]

Toxins (Basel), 2019
Botulinum neurotoxin (BoNT) can counteract the highly frequent involuntary muscle contractions and the uncontrolled micturition events that characterize the neurogenic detrusor overactivity (NDO) due to supra-sacral spinal cord lesions. The ability of the toxin to block the neurotransmitter vesicular release causes the reduction of contractions and ...
Traini C, Vannucchi MG.
europepmc   +5 more sources

Incidence of Urinary Retention Following OnabotulinumtoxinA: A Multi‐Centre Audit Challenging the Necessity of Universal CISC Training

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background Clinical guidelines, such as NICE NG123, prior to OnabotulinumtoxinA (BoNT‐A) injections for overactive bladder (OAB), patients are counselled regarding clean intermittent self‐catheterisation (CISC) and are willing and able to perform catheterisation if required. Subsequently, universal pre‐procedure education imposes a significant
Faysal elzawy, Mark Roger, Shazad Laghari, Ali alali, Mathew Thomas, Prateek Verma   +5 more
wiley   +1 more source

Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity

International Brazilian Journal of Urology, 2010
PURPOSE: To evaluate the efficacy of botulinum toxin type A injections in the detrusor muscle in patients with spinal cord injury and urinary incontinence due to detrusor overactivity and refractory to anticholinergic agents.
Ronaldo A. Alvares, Jose A. F. Silva, Andre L. Barboza, Raphael T. M. Monteiro   +3 more
doaj   +1 more source

Fear‐Avoidance and Overactive Bladder: Toward a Mechanism‐Informed Model of Care

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims Overactive bladder (OAB) is associated with substantial psychological burden, yet existing biopsychosocial frameworks acknowledge that psychological factors shape outcomes without explaining the cognitive and behavioral mechanisms through which that influence operates.
Rupal M. Patel, Andrea Wood
wiley   +1 more source

Predictors of 2‐Week Post‐Void Residual After Intradetrusor OnabotulinumtoxinA Injection for Overactive Bladder: A Sex‐ and Neurogenic Status‐Stratified Analysis

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objective Urinary retention rates after intradetrusor onabotulinumtoxinA (BTX‐A) peak at 2 weeks, yet risk stratification by sex and neurogenic status remains limited. We evaluated predictors of 2‐week post‐void residual (PVR) and differences by sex and neurogenic bladder status using the largest retrospective cohort to date.
Saawan D. Patel, Evan Rosario, Ariana L. Smith   +2 more
wiley   +1 more source

Botulinum toxin and refractory non-neurogenic overactive detrusor

Annals of Physical and Rehabilitation Medicine, 2009
To study the value and efficacy of botulinum toxin for treatment of cases of non-neurogenic detrusor overactivity (NNDO) that are refractory to anticholinergic drugs.A systematic review of the literature, based on a keyword search of the Medline database.
Ksibi, I., Godard, A.-L., Azouvi, P., Denys, P., Dziri, C.   +4 more
openaire   +2 more sources